KATE MIMKEN: Open Payments
NPI 1912426578 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,673 in 37 payments from 19 companies in 2025. Trend: 2023 $1,912 · 2024 $583 · 2025 $2,673
Consulting: $1,508Food & beverage: $1,165
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $908 |
| GlaxoSmithKline, LLC. | 2 | $800 |
| GENZYME CORPORATION | 3 | $261 |
| BeOne Medicines USA, Inc. | 2 | $152 |
| ABBVIE INC. | 7 | $140 |
| Celgene Corporation | 2 | $50 |
| PFIZER INC. | 3 | $50 |
| Incyte Corporation | 2 | $50 |
| Azurity Pharmaceuticals, Inc. | 2 | $36 |
| Merck Sharp & Dohme LLC | 1 | $27 |
Products named: SARCLISA, BRUKINSA, VENCLEXTA, EPKINLY, REBLOZYL, ELREXFIO, DANZITEN, IMBRUVICA.
Industry payments across CO — which companies pay providers there.
